European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/21/2026

1. SPY
2. TSLA
3. WBD
4. AMC
5. MSFT
6. AMZN
7. ACN
8. FFAI
9. PAA
10. TLT

Go back to European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma
Merck & Co. (NYSE: MRK) Delayed: 148.73 +1.86 (1.27%)
Previous Close $146.87    52 Week High $65.46 
Open $146.79    52 Week Low $47.97 
Day High $149.19    P/E 101.18 
Day Low $145.60    EPS $1.47 
Volume 1,034,232